Hugely encouraging results for Novartis‘ new experimental (oral) MS treatment – Novartis’ Gilena has delivered an impressive performance in a Phase III trial in patients multiple sclerosis, cutting relapse rates by 62% in treatment-naïve patients and sustaining its effects for more than two years. Importantly, data from the two-year FREEDOMS study, presented at the American Academy of Neurology annual meeting, also showed that relapse rates were reduced by a significant 44% in patients who had previously been treated with other drugs for MS, highlighting the potential benefit of switching therapies…more
Gilead starts late stage testing of “4-in-1” HIV pill.
An interesting account of regulatory “unintended consequences.” How to make a cheap drug very expensive.
Cephalon hopes to gain more cheddar by adding some Swiss. Sorry – couldn’t resist…
Celgene: the new “big kid” on the block.
Coaching Skills – The Impactiviti Partner Network is your resource if you’re looking to improve the coaching skills of your employees. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.
An amusing patient health video made by J&J. Well worth 4 minutes of your time. The Appointment.
JUST FOR FUN
Oldie but goodie from The Onion – American to start charging fees to Non-passengers.
Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)
Visit the Impactiviti Job Board